Oncoclínicas do Brasil Serviços Médicos Future Growth
Future criteria checks 4/6
Oncoclínicas do Brasil Serviços Médicos is forecasted to grow earnings and revenue by 36.3% and 14.3% per annum respectively. EPS is expected to grow by 55.7%. Return on equity is forecast to be 16.4% in 3 years.
Key information
36.3%
Earnings growth rate
55.7%
EPS growth rate
Healthcare earnings growth | 43.4% |
Revenue growth rate | 14.3% |
Future return on equity | 16.4% |
Analyst coverage | Good |
Last updated | 14 Sep 2023 |
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | 7,526 | 608 | 1,053 | 1,953 | 7 |
12/31/2024 | 6,607 | 469 | 778 | 1,558 | 9 |
12/31/2023 | 5,518 | 200 | 1,169 | 1,690 | 7 |
6/30/2023 | 5,033 | 145 | -253 | 78 | N/A |
3/31/2023 | 4,574 | 91 | -646 | -346 | N/A |
12/31/2022 | 4,088 | 46 | -576 | -272 | N/A |
9/30/2022 | 3,640 | -10 | -740 | -378 | N/A |
6/30/2022 | 3,155 | 105 | -593 | -324 | N/A |
3/31/2022 | 2,895 | -67 | -415 | -185 | N/A |
12/31/2021 | 2,702 | -47 | -211 | -9 | N/A |
9/30/2021 | 2,509 | -203 | -138 | 27 | N/A |
6/30/2021 | 2,354 | -334 | -128 | 9 | N/A |
3/31/2021 | 2,182 | -145 | -17 | 154 | N/A |
12/31/2020 | 2,035 | -158 | -19 | 186 | N/A |
12/31/2019 | 1,690 | -20 | -93 | 97 | N/A |
12/31/2018 | 1,051 | -17 | -296 | -18 | N/A |
12/31/2017 | 792 | 3 | 101 | 135 | N/A |
12/31/2016 | 595 | -25 | N/A | -21 | N/A |
12/31/2015 | 458 | -25 | N/A | -3 | N/A |
12/31/2014 | 359 | -22 | N/A | 9 | N/A |
12/31/2013 | 269 | 21 | N/A | 7 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ONCO3's forecast earnings growth (36.3% per year) is above the savings rate (9.7%).
Earnings vs Market: ONCO3's earnings (36.3% per year) are forecast to grow faster than the BR market (12.3% per year).
High Growth Earnings: ONCO3's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: ONCO3's revenue (14.3% per year) is forecast to grow faster than the BR market (6.4% per year).
High Growth Revenue: ONCO3's revenue (14.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ONCO3's Return on Equity is forecast to be low in 3 years time (16.4%).